Ensuring impact of long-acting HIV therapeutics through multi-level treatment research: a view from NIH.
作者信息
Kim Peter S, Stirratt Michael J, Morton Tia M, Rausch Dianne M
机构信息
Therapeutics Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, Maryland, USA.
Division of AIDS Research, National Institute of Mental Health (NIMH), National Institutes of Health, Bethesda, Maryland, USA.
出版信息
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26091. doi: 10.1002/jia2.26091.
Abstract
摘要
相似文献
1
Ensuring impact of long-acting HIV therapeutics through multi-level treatment research: a view from NIH.通过多层次治疗研究确保长效HIV治疗药物的疗效：美国国立卫生研究院的观点
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26091. doi: 10.1002/jia2.26091.
2
Extending access with long-acting antiretroviral therapy: the next advance in HIV-1 therapeutics and prevention.通过长效抗逆转录病毒疗法扩大可及性：HIV-1治疗与预防的下一个进展。
Curr Opin HIV AIDS. 2015 Jul;10(4):216-8. doi: 10.1097/COH.0000000000000167.
3
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).通过评估每 4 或 8 周给药的长效卡替拉韦和利匹韦林的 HIV-1 临床试验，患者报告结果在 1 年内的情况（ATLAS-2M）。
Patient. 2021 Nov;14(6):849-862. doi: 10.1007/s40271-021-00524-0. Epub 2021 May 31.
4
Long-acting injectable HIV therapies: the next frontier.长效注射型 HIV 疗法：下一个前沿。
Curr Opin Infect Dis. 2021 Feb 1;34(1):8-15. doi: 10.1097/QCO.0000000000000701.
5
Provision of immediate postpartum contraception to women living with HIV in the Eastern Cape, South Africa; a cross-sectional analysis.南非东开普省为艾滋病毒感染者产妇提供即时产后避孕措施：一项横断面分析。
Reprod Health. 2020 Dec 9;17(1):194. doi: 10.1186/s12978-020-01049-9.
6
Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV.在开发长效注射剂以预防和治疗 HIV 的同时，应对全球乙型肝炎病毒负担。
Lancet HIV. 2020 Jun;7(6):e443-e448. doi: 10.1016/S2352-3018(19)30342-X. Epub 2019 Dec 20.
7
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.长效卡博替拉韦加利匹韦林用于治疗成人 HIV-1 感染：随机、开放标签、3 期 FLAIR 研究的 96 周结果。
Lancet HIV. 2021 Apr;8(4):e185-e196. doi: 10.1016/S2352-3018(20)30340-4.
8
Long-Acting Antiretrovirals: Where Are We now?长效抗逆转录病毒药物：我们现在处于什么阶段？
Curr HIV/AIDS Rep. 2017 Apr;14(2):63-71. doi: 10.1007/s11904-017-0353-0.
9
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.长效卡博特韦和利匹韦林用于 HIV-1 感染的口服诱导后。
N Engl J Med. 2020 Mar 19;382(12):1124-1135. doi: 10.1056/NEJMoa1909512. Epub 2020 Mar 4.
10
Will Long-Acting Antiretroviral Therapy be a Game Changer Globally?长效抗逆转录病毒疗法能否在全球引发变革？
Med. 2021 Feb 12;2(2):115-117. doi: 10.1016/j.medj.2021.01.004.
引用本文的文献
1
Real-world Rollout of Injectable Antiretrovirals for HIV Prevention and Treatment: Correlates of Early Adoption.用于艾滋病毒预防和治疗的注射用抗逆转录病毒药物的实际推广：早期采用的相关因素。
Open Forum Infect Dis. 2025 Jan 20;12(2):ofaf029. doi: 10.1093/ofid/ofaf029. eCollection 2025 Feb.
2
Advancing use of long-acting and extended delivery HIV prevention and treatment regimens.推进长效和缓释型艾滋病毒预防与治疗方案的应用。
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26126. doi: 10.1002/jia2.26126.
本文引用的文献
1
Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.HIV-1 感染者对长效卡替拉韦/利匹韦林在美国医疗环境中实施的看法：来自 CUSTOMIZE 混合 III 实施有效性研究的结果。
J Int AIDS Soc. 2022 Sep;25(9):e26006. doi: 10.1002/jia2.26006.
2
First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable Human Immunodeficiency Virus (HIV) Viremia in an Urban HIV Clinic.长效注射型抗逆转录病毒疗法在城市 HIV 诊所中针对有/无症状 HIV 病毒血症患者的首次示范项目。
Clin Infect Dis. 2023 Feb 8;76(3):e645-e651. doi: 10.1093/cid/ciac631.
3
Intersectional stigmas are associated with lower viral suppression rates and antiretroviral therapy adherence among women living with HIV.交叉污名与艾滋病毒感染者女性的病毒抑制率较低和抗逆转录病毒治疗依从性较差有关。
AIDS. 2022 Nov 1;36(13):1769-1776. doi: 10.1097/QAD.0000000000003342. Epub 2022 Jul 25.
4
Prolonged viral suppression with anti-HIV-1 antibody therapy.抗 HIV-1 抗体治疗实现病毒长期抑制。
Nature. 2022 Jun;606(7913):368-374. doi: 10.1038/s41586-022-04597-1. Epub 2022 Apr 13.
5
Impact of long-acting therapies on the global HIV epidemic.长效治疗对全球艾滋病毒流行的影响。
AIDS. 2021 Dec 15;35(Suppl 2):S137-S143. doi: 10.1097/QAD.0000000000003102.
6
The HIV Treat Pillar: An Update and Summary of Promising Approaches.HIV 治疗药物柱：有前途的方法的更新和总结。
Am J Prev Med. 2021 Nov;61(5 Suppl 1):S39-S46. doi: 10.1016/j.amepre.2021.05.028.
7
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).通过评估每 4 或 8 周给药的长效卡替拉韦和利匹韦林的 HIV-1 临床试验，患者报告结果在 1 年内的情况（ATLAS-2M）。
Patient. 2021 Nov;14(6):849-862. doi: 10.1007/s40271-021-00524-0. Epub 2021 May 31.
8
Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine.长效肌内注射卡替拉韦和利匹韦林的药代动力学和药物相互作用。
Clin Pharmacokinet. 2021 Jul;60(7):835-853. doi: 10.1007/s40262-021-01005-1. Epub 2021 Apr 8.
9
Pilot Randomized Controlled Trial of an Intervention to Improve Coping with Intersectional Stigma and Medication Adherence Among HIV-Positive Latinx Sexual Minority Men.拉丁裔性少数男性艾滋病毒感染者应对交叉污名和药物依从性干预的初步随机对照试验
AIDS Behav. 2021 Jun;25(6):1647-1660. doi: 10.1007/s10461-020-03081-z. Epub 2020 Nov 24.
10
Cumulative Effects of Stigma Experiences on Retention in HIV Care Among Men and Women in the Rural Southeastern United States.美国东南部农村地区男男性行为者和女性 HIV 感染者经历污名对其坚持接受 HIV 护理的累积影响
AIDS Patient Care STDS. 2020 Nov;34(11):484-490. doi: 10.1089/apc.2020.0144.
Zotero 插件